|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0055598,
umls-concept:C0079744,
umls-concept:C0215027,
umls-concept:C0332281,
umls-concept:C0393022,
umls-concept:C0871261,
umls-concept:C1413947,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1882417,
umls-concept:C2911692
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2007-7-3
|
|
pubmed:abstractText |
We investigated the association ofFcgammaRIIIaa and FcgRIIa polymorphisms and response to R-CHOP in 58 patients with diffuse large B-cell lymphoma (DLBCL). FcgammaRIIIa and FcgRIIa polymorphisms did not influence response, event-free or overall survival. These results suggest that ADCC via FcgammaRIIIa and FcgammaRIIa may not be the major mechanism of activity of the R-CHOP combination in DLBCL.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/FCGR3A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Fc gamma receptor IIA,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, IgG,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1592-8721
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
92
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
998-9
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17606457-Adolescent,
pubmed-meshheading:17606457-Adult,
pubmed-meshheading:17606457-Aged,
pubmed-meshheading:17606457-Antibodies, Monoclonal,
pubmed-meshheading:17606457-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:17606457-Antigens, CD,
pubmed-meshheading:17606457-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17606457-Cyclophosphamide,
pubmed-meshheading:17606457-Doxorubicin,
pubmed-meshheading:17606457-Female,
pubmed-meshheading:17606457-Humans,
pubmed-meshheading:17606457-Lymphoma, B-Cell,
pubmed-meshheading:17606457-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:17606457-Male,
pubmed-meshheading:17606457-Middle Aged,
pubmed-meshheading:17606457-Polymorphism, Genetic,
pubmed-meshheading:17606457-Prednisone,
pubmed-meshheading:17606457-Receptors, IgG,
pubmed-meshheading:17606457-Survival Analysis,
pubmed-meshheading:17606457-Treatment Outcome,
pubmed-meshheading:17606457-Vincristine
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma.
|
|
pubmed:affiliation |
Division of Hematology, Department of Internal Medicine, University Hospital Center and Medical School University of Zagreb, Croatia. mitrovic@mef.hr
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
